Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Emergent Biosolutions Inc. (EBS : NYSE)
 
 • Company Description   
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.

Number of Employees: 2,416

 
 • Price / Volume Information   
Yesterday's Closing Price: $28.62 Daily Weekly Monthly
20 Day Moving Average: 693,097 shares
Shares Outstanding: 50.24 (millions)
Market Capitalization: $1,437.97 (millions)
Beta: 0.98
52 Week High: $68.03
52 Week Low: $27.61
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.49% -22.74%
12 Week -31.56% -25.74%
Year To Date -34.16% -21.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 PROFESSIONAL DR SUITE 400
-
GAITHERSBURG,MD 20879
USA
ph: 240-631-3200
fax: 301-795-1899
burrowsr@ebsi.com http://www.emergentbiosolutions.com
 
 • General Corporate Information   
Officers
Robert G. Kramer - Chief Executive Officer;President
Fuad El-Hibri - Executive Chairman of the Board of Directors
Richard S. Lindahl - Executive Vice President; Chief Financial Officer
Zsolt Harsanyi - Director
Kathryn Zoon - Director

Peer Information
Emergent Biosolutions Inc. (CORR.)
Emergent Biosolutions Inc. (RSPI)
Emergent Biosolutions Inc. (CGXP)
Emergent Biosolutions Inc. (BGEN)
Emergent Biosolutions Inc. (GTBP)
Emergent Biosolutions Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29089Q105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 50.24
Most Recent Split Date: (:1)
Beta: 0.98
Market Capitalization: $1,437.97 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.63 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.02 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 28.15
Trailing 12 Months: 6.15
PEG Ratio: -
Price Ratios
Price/Book: 0.91
Price/Cash Flow: 3.39
Price / Sales: 0.82
EPS Growth
vs. Year Ago Period: -88.24%
vs. Previous Quarter: -96.00%
Sales Growth
vs. Year Ago Period: -10.35%
vs. Previous Quarter: -57.48%
ROE
03/31/22 - 16.05
12/31/21 - 20.99
09/30/21 - 18.63
ROA
03/31/22 - 8.72
12/31/21 - 11.19
09/30/21 - 9.72
Current Ratio
03/31/22 - 4.42
12/31/21 - 3.40
09/30/21 - 3.04
Quick Ratio
03/31/22 - 2.81
12/31/21 - 2.46
09/30/21 - 2.04
Operating Margin
03/31/22 - 14.30
12/31/21 - 18.17
09/30/21 - 17.01
Net Margin
03/31/22 - 8.96
12/31/21 - 12.88
09/30/21 - 13.74
Pre-Tax Margin
03/31/22 - 12.83
12/31/21 - 17.54
09/30/21 - 18.14
Book Value
03/31/22 - 31.35
12/31/21 - 30.09
09/30/21 - 28.30
Inventory Turnover
03/31/22 - 2.17
12/31/21 - 2.01
09/30/21 - 1.71
Debt-to-Equity
03/31/22 - 0.51
12/31/21 - 0.50
09/30/21 - 0.54
Debt-to-Capital
03/31/22 - 33.72
12/31/21 - 33.33
09/30/21 - 34.93
 

Powered by Zacks Investment Research ©